Wim J Kirkels
Overview
Explore the profile of Wim J Kirkels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1199
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Remmers S, de Vos I, Denijs F, Leenen R, Lock T, Noordzij A, et al.
Eur Urol Open Sci
. 2024 Dec;
71:11-14.
PMID: 39641118
Patient Summary: We compared the classification of prostate cancer death between a dedicated trial committee and official statistics in the Netherlands. We found that official statistics are an accurate representation...
2.
Oddens J, Sylvester R, Brausi M, Kirkels W, van de Beek C, van Andel G, et al.
BJU Int
. 2016 Mar;
118(3):423-8.
PMID: 26945890
Objective: To determine the relationship of age to side-effects leading to discontinuation of treatment in patients with stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with maintenance bacille Calmette-Guérin (BCG). Patients...
3.
Aluwini S, Busser W, Alemayehu W, Boormans J, Kirkels W, Jansen P, et al.
Radiother Oncol
. 2015 Sep;
117(2):252-7.
PMID: 26409832
Background And Purpose: The use of HDR brachytherapy (HDR-BT) as monotherapy for prostate cancer (PC) is increasing worldwide with good tumour control rates and acceptable toxicity. We report our results...
4.
Cambier S, Sylvester R, Collette L, Gontero P, Brausi M, van Andel G, et al.
Eur Urol
. 2015 Jul;
69(1):60-9.
PMID: 26210894
Background: There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with 1-3 yr of maintenance bacillus Calmette-Guérin (BCG). Objective: To determine prognostic factors in NMIBC...
5.
van Rhijn B, Musquera M, Liu L, Vis A, Zuiverloon T, van Leenders G, et al.
Mod Pathol
. 2014 Nov;
28(5):695-705.
PMID: 25431236
Currently, the use of two classification systems for bladder cancer grade is advocated in clinical guidelines because the WHO2004 classification has not been sufficiently validated with biological markers and follow-up....
6.
Oddens J, Sylvester R, Brausi M, Kirkels W, van de Beek C, van Andel G, et al.
Eur Urol
. 2014 Jun;
66(4):694-701.
PMID: 24948466
Background: Although maintenance bacillus Calmette-Guérin (BCG) is the recommended treatment in high-risk non-muscle-invasive bladder cancer (NMIBC), its efficacy in older patients is controversial. Objective: To determine the effect of age...
7.
Aluwini S, van Rooij P, Kirkels W, Boormans J, Kolkman-Deurloo I, Wijnmaalen A
Int J Radiat Oncol Biol Phys
. 2014 Jan;
88(3):611-7.
PMID: 24411629
Purpose: To report long-term results of a bladder preservation strategy for muscle-invasive bladder cancer (MIBC) using external beam radiation therapy and brachytherapy/interstitial radiation therapy (IRT). Methods And Materials: Between May...
8.
Roobol M, Kranse R, Bangma C, van Leenders A, Blijenberg B, van Schaik R, et al.
Eur Urol
. 2013 Jun;
64(4):530-9.
PMID: 23759326
Background: Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective: To assess data on PCa-specific mortality in...
9.
Aluwini S, van Rooij P, Kirkels W, Jansen P, Praag J, Bangma C, et al.
Int J Radiat Oncol Biol Phys
. 2012 Jan;
83(5):1480-5.
PMID: 22285661
Purpose: To report clinical outcomes and early and late complications in 264 hormone-naïve patients with low- and intermediate-risk prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) in combination with external-beam radiotherapy...
10.
Zuiverloon T, Nieuweboer A, Vekony H, Kirkels W, Bangma C, Zwarthoff E
Eur Urol
. 2011 Oct;
61(1):128-45.
PMID: 22000498
Context: Currently, bacillus Calmette-Guérin (BCG) intravesical instillations are standard treatment for patients with high-grade non-muscle-invasive bladder cancer; however, no markers are available to predict BCG response. Objective: To review the...